BridgeMD
New treatment option for Acute Ischemic Stroke
Official title Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke
ClinicalTrials.gov ID: NCT05604638
What this study is testing
What is Tirofiban Hydrochloride?
Tirofiban Hydrochloride is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for acute ischemic stroke.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to assess the safety and efficacy of early administration of tirofiban in patients treated with tenecteplase for acute ischemic stroke.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years old;
- Within 4-24 hours after intravenous thrombolytic therapy with tenerplase for acute ischemic stroke, there was no significant change in symptoms...
- NIHSS ≥ 4 points before randomization;
- The patient or their family members sign a written informed consent form.
You likely can't join if
- Intracranial hemorrhage was confirmed by CT or MRI after intravenous thrombolysis and before randomization;
- CTA/MRA/DSA showed occlusion of the internal carotid artery, middle cerebral artery M1, M2 or M3 segment, anterior cerebral artery A1, A2 or A3...
- Confirmed or suspected cardioembolic stroke mechanisms, including any of the following: documented cardiac sources of thromboembolism: chronic or...
- Blood platelet count was lower than 100×10\^9/L;
- Renal insufficiency, glomerular filtration rate \< 30 mL/min;
- Pregnant or lactating women;
See the full eligibility criteria
- Age ≥ 18 years old;
- Within 4-24 hours after intravenous thrombolytic therapy with tenerplase for acute ischemic stroke, there was no significant change in symptoms compared to the baseline (defined as an increase or decrease of 0 or 1...
- NIHSS ≥ 4 points before randomization;
- The patient or their family members sign a written informed consent form.
- Intracranial hemorrhage was confirmed by CT or MRI after intravenous thrombolysis and before randomization;
- CTA/MRA/DSA showed occlusion of the internal carotid artery, middle cerebral artery M1, M2 or M3 segment, anterior cerebral artery A1, A2 or A3 segment, posterior cerebral artery P1, P2 or P3, vertebral or basilar...
- Confirmed or suspected cardioembolic stroke mechanisms, including any of the following: documented cardiac sources of thromboembolism: chronic or paroxysmal atrial fibrillation, rheumatic mitral stenosis, prosthetic...
- Blood platelet count was lower than 100×10\^9/L;
- Renal insufficiency, glomerular filtration rate \< 30 mL/min;
- Pregnant or lactating women;
- Allergic to tirofiban, nickel, titanium or their alloys;
- Prior neurological or psychiatric illness that prevents assessment of neurological function;
- Pre-existing bleeding disease, severe heart, liver, or kidney disease, or sepsis;
- Brain tumors with a space-occupying effect on imaging (other than micromeningiomas);
- Intracranial aneurysm, arteriovenous malformation;
- Life expectancy of any advanced disease \< 6 months;
- Participating in other clinical trials.
The study team makes the final eligibility decision.
Where it's taking place
- Chuzhou, Anhui, China
- Longyan, Fujian, China
- Nanning, Guangxi, China
- Huanggang, Hubei, China
- Yichang, Hubei, China
- Huaihua, Hunan, China
- Shaoyang, Hunan, China
- Xiangtan, Hunan, China
- Yueyang, Hunan, China
- Ganzhou, Jiangxi, China
- Jiujiang, Jiangxi, China
- Ji’an, Jiangxi, China
- Nanchang, Jiangxi, China
- Yichun, Jiangxi, China
- Yingtan, Jiangxi, China
- Songyuan, Jilin, China
- Dalian, Liaoning, China
- Chifeng, Neimenggu, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chuzhou, Anhui, China; Longyan, Fujian, China; Nanning, Guangxi, China; Huanggang, Hubei, China; Yichang, Hubei, China; Huaihua, Hunan, China and 12 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.